The overall objective is to collect and assess data on the treatment, safety, and treatment outcomes of subjects prescribed, receiving and participating in the Ceprotin treatment registry.
Study Type
OBSERVATIONAL
Enrollment
43
Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Orange, California, United States
Medical diagnoses associated with Ceprotin treatment
Time frame: 2 to 5 years, or until the Registry is terminated
Ceprotin treatment regimens
Time frame: 2 to 5 years, or until the Registry is terminated
Safety information based on all serious adverse events (SAEs), related SAEs and related non-serious adverse events (AEs)
Time frame: 2 to 5 years, or until the Registry is terminated
Treatment outcomes categorized by medical diagnosis
Evidence of halting or reversal of coagulopathy or thrombosis, end-organ damage, limb sparing, Length of Hospital Stay (LOS), and mortality
Time frame: 2 to 5 years, or until the Registry is terminated
CEPROTIN use and treatment outcomes in pregnancy, labor and delivery, surgery and invasive procedures, different age groups, and, in the presence of pre-existing renal and/or hepatic dysfunction
Time frame: 2 to 5 years, or until the Registry is terminated
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Aurora, Colorado, United States
Unnamed facility
Indianapolis, Indiana, United States
Unnamed facility
Boston, Massachusetts, United States
Unnamed facility
Grand Rapids, Michigan, United States
Unnamed facility
Lebanon, New Hampshire, United States
Unnamed facility
Cincinnati, Ohio, United States
Unnamed facility
Columbus, Ohio, United States
Unnamed facility
Dayton, Ohio, United States
...and 18 more locations